53rd week of 2015 patent applcation highlights part 8 |
Patent application number | Title | Published |
20150374599 | FLAVOUR AND FRAGRANCE COMPOSITIONS COMPRISING ACETOPHENONE DERIVATIVES - Suggested are new flavour and fragrance compositions comprising selected acetophenone derivatives for dissolving flavours and fragrances, and further especially for dissolving lipophilic compounds, which are implemented in these products. | 2015-12-31 |
20150374600 | METHODS AND PREPARATIONS THAT TREAT HUMAN HAIR LOSS - The current document is directed to methods that ameliorate and/or reverse human hair-loss. The methods render hair follicles accessible to treatment agents that remove blocking oil and cell remnants to allow additional treatment agents to enter the pilosebaceous units to kill or control microbes that disrupt hair growth by changing, inhibiting, or interrupting one or more biological functions of the pilosebaceous units. | 2015-12-31 |
20150374601 | DYE COMPOSITION USING AT LEAST ONE COUPLER OF META-PHENYLENEDIAMINE TYPE SUBSTITUTED IN POSITION 2 IN A MEDIUM COMPRISING A FATTY SUBSTANCE, PROCESSES AND DEVICE - The present invention relates to a composition for dyeing keratin fibres, in particular human keratin fibres, comprising one or more fatty substances, one or more surfactants, one or more oxidation bases, one or more particular couplers of meta-phenylenediamine type substituted in position 2, and one or more basifying agents, the fatty substance content in the dye composition representing in total at least 5% by weight relative to the total weight of the said composition. The invention also relates to a dyeing process using such a composition, and also to multi-compartment devices suitable for performing the said process. | 2015-12-31 |
20150374602 | MULTI-TONAL ONE STEP DYES III - A cosmetic agent (A) is applied to the fibers and is allowed to act for a period of 30 seconds to 30 minutes, after which a cosmetic agent (B) is applied to the keratinic fibers, which continue to be acted on by agent (A). Both agents (A) and (B) are allowed to act for a period of 5 to 45 minutes, after which the agents (A) and (B) are rinsed out. Agent (A) (a1) contains no oxidation dye precursors of the developer type, (a2) contains one or more oxidation dye precursors of the coupler type, (a3) has a pH of 8.0 to 12.0, and agent (B) (b) contains one or more oxidation dye precursors, (b2) contains one or more oxidizing agents, and (b3) has a pH of 8.0 to 12.0. | 2015-12-31 |
20150374603 | HAIR GROWTH COMPOSITION AND METHOD - The present invention relates to compositions for and methods of retarding hair loss or facilitating hair growth comprising a hair growth active and a C | 2015-12-31 |
20150374604 | SEMI-PERMANENT HAIR STRAIGHTENING COMPOSITION AND METHOD - A composition and a process for straightening hair are disclosed. The process includes coating keratin fibers with a composition comprising a thermally-activated agent and contacting the coated keratin fibers with a heating device at a temperature of at least 185° C. for sufficient time to modify the keratin fibers. The thermally-activated agent comprises a heterocyclic compound containing two heteroatoms selected from nitrogen and oxygen in a 5 or 6-membered ring, such as a cyclic alkylene carbonate. | 2015-12-31 |
20150374605 | USE OF A COMPOSITION COMPRISING AVOCADO PERSEOSE IN THE PROTECTION OF EPIDERMAL STEM CELLS - The invention concerns a use of C7 sugars and derivatives of formula (I), called avocado perseose, which have, inter alia, a protective activity to epidermal skin cells. These C7 sugars and derivatives are capable of maintaining the expression of markers of adult stem cells, in particular basal stem cells. Avocado perseose can also be used for preventing the deleterious effects of environmental damage. Avocado perseose has a beneficial effect on the conservation of the potential of epidermal stem cells and thus helps maintain skin homeostasis. | 2015-12-31 |
20150374606 | TETRAPEPTIDES AND A METHOD OF USE AS AN ANTIOXIDANT - A tetrapeptide having antioxidant activity is provided. The tetrapeptide has a structure comprising, in amino acid sequence from N-terminus to C-terminus: tryptophan-X-tyrosine-X; wherein X is arginine, lysine, histidine or any positively-charged amino acid derivative such as 5-hydroxylysine, ornithine, 2,4-diamino-butyrate and 2,3-diamino-propionate. Each amino acid of the sequence or its Homo-amino acid derivative is independently of the D configuration (D-stereoisomer) or of the L configuration (L-stereoisomer), and the C-terminal comprises one selected from the group consisting of carboxyl (—COOH), and carboxamide (—CONH | 2015-12-31 |
20150374607 | TOPICAL USE OF A SKIN-COMMENSAL PREBIOTIC AGENT AND COMPOSITIONS CONTAINING THE SAME - A topical cosmetic composition that includes a dermatologically acceptable carrier and an effective amount of a skin commensal prebiotic to improve the health of the skin microbiome, thereby potentially improving the condition and/or appearance of the skin. The topical cosmetic compositions may be made by identifying a potential skin commensal prebiotic agent using a first in vitro assay; confirming the prebiotic potential of an identified prebiotic agent with a second in vitro assay or an in vivo assay; and mixing a confirmed prebiotic agent from and a dermatologically acceptable carrier to form a topical cosmetic composition. | 2015-12-31 |
20150374608 | HAIR CONDITIONING COMPOSITION COMPRISING AMIDOAMINE CATIONIC SURFACTANT AND DEPOSITION POLYMER AND HAVING LOWER PH - Disclosed is a hair conditioning composition comprising: a mono-alkyl amine cationic surfactant; a high melting point fatty compound; an anionic polymer comprising higher % of a vinyl monomer (A) with a carboxyl group; and an aqueous carrier, wherein the composition has a pH of 4 or less. The present invention provides hair conditioning compositions having reduced chunks while containing both mono-alkyl amine cationic surfactants and anionic polymers containing higher % of vinyl monomer with carboxyl group. | 2015-12-31 |
20150374609 | Personal Care Compositions and Methods - Methods of making personal care compositions including microcapsules and methods of enhancing the efficacy of the microcapsules in said personal care compositions. | 2015-12-31 |
20150374610 | TOPICAL PROTECTIVE POLYMERIZED NANOPARTICLES IN AN ACTIVE OR BIOACTIVE ARRAY, METHODS FOR PREPARING SAME AND USES THEREOF - The invention concerns a compound formed by functionalised micro- or nanoparticles covalently associated with rheology-modifying polymers. The invention is characterised in that the functionalised micro- or nanoparticles are functionalised inorganic or metal oxide micro- or nanoparticles, in particular aluminium oxide (Al | 2015-12-31 |
20150374611 | COMPOSITION FOR REDUCING THE TIME NEEDED TO DRY WET HAIR - A cosmetic composition useful to reduce the drying time of wet hair is disclosed. The composition includes a nonaqueous combination of a volatile silicone compound, such as cyclopentasiloxane, and a mixture of one or more silicone elastomers. The silicone elastomers may include, but are not limited to, dimethicone, cetearyl dimethicone crosspolymers, dimethicone crosspolymers, dimethicone/vinyl dimethicone crosspolymers, and dimethiconol. | 2015-12-31 |
20150374612 | ORGANOPOLYSILOXANE GRAFT POLYMER - The present invention relates to an organopolysiloxane graft polymer including an organopolysiloxane segment as a main chain thereof and an unsaturated monomer-derived copolymer segment containing a repeating unit derived from an unsaturated monomer containing a carboxylic acid or a carboxylic acid salt as a side chain thereof, in which a content of the organopolysiloxane segment in the organopolysiloxane graft polymer is 35 to 59% by mass, a content of the repeating unit derived from the unsaturated monomer containing a carboxylic acid or a carboxylic acid salt in the organopolysiloxane graft polymer is 4 to 17% by mass, and a content of a repeating unit derived from an unsaturated monomer whose homopolymer has a glass transition point of not lower than 150° C. (except for the unsaturated monomer containing a carboxylic acid or a carboxylic acid salt) in the organopolysiloxane graft polymer is not more than 14% by mass, and a number-average molecular weight of the organopolysiloxane segment is not less than 8,000 and not more than 200,000. | 2015-12-31 |
20150374613 | HAIR LOSS PREVENTION AND RESTORATION SOLUTION - The embodied invention generally pertains to compositions, and the methods of making and using said compositions for promoting hair growth, slowing hair loss, and for preventing or minimizing hair loss that are effective and able to treat multiple aspects of the problem in one product and additionally is comprised of natural oils and minerals which greatly reduce the toxicities and side effect issues associated with present products. The compositions or formulations of the present invention relate to a hair loss solution that solves the problems associated with the loss, and damage of hair by working from the root to the surface of the scalp and to the hair shaft by treating a plurality of the causes and/or triggers associated with hair loss, or the prevention of hair re-growth. | 2015-12-31 |
20150374614 | Use of Orange Essential Oil to Treat Skin Pigmentation Disorders - The present invention concerns the cosmetic and/or dermatological use of at least one essential oil of sweet orange to prevent and/or treat skin pigmentation disorders. | 2015-12-31 |
20150374615 | Method For Facilitating The Growth of Hair - A method of growing hair is disclosed. The method comprising: providing a plurality of date seeds; inserting the plurality of date seeds in an oven for a certain period of time; baking the plurality of date seeds in the oven; grinding the plurality of date seeds to form a paste; mixing the paste with a plurality of oils to form an oily paste; placing the oily paste in an environment to sit; and applying the oily paste to a head of at least one person to grow hair on the head of the at least one person. | 2015-12-31 |
20150374616 | Topical Skin Care Formulations Comprising Jaboticaba and Cashew Fruit Pulps and Extracts Thereof - Disclosed are compositions and corresponding methods of their use that include jaboticaba fruit pulp and/or cashew fruit pulp or extracts thereof. | 2015-12-31 |
20150374617 | TETRACERA ASIATICA EXTRACTS AND METHODS OF USE - Methods of using extracts of | 2015-12-31 |
20150374618 | HEDYOTIS HEDROTIDEA EXTRACTS FOR COSMETICS - Methods of using extracts of Hedyotis hedyotidea to impart benefits to skin and/or improve skin conditions resulting from aging or damaged skin. | 2015-12-31 |
20150374619 | ABUTILON INDICUM EXTRACTS AND METHODS OF USE - Methods of using extracts of | 2015-12-31 |
20150374620 | Microneedle-Coating Composition and Microneedle Device - Disclosed is a microneedle coating composition comprising a physiologically active substance (excluding Japanese encephalitis vaccine antigen), a basic amino acid, and an acid, wherein the mole number of the acid for one mole of the basic amino acid is larger than 1/(N+1) and less than 2, where N represents the valence of the acid. | 2015-12-31 |
20150374621 | USE OF SELECTED ANTICHOLINERGIC ZWITTERIONS - Selected anticholinergic zwitterions are administered to slow the progression of myopia in children and to treat myopia generally. | 2015-12-31 |
20150374622 | CHEWABLE COMPOSITION FOR ORAL ADMINISTRATION AND PROCESS FOR PREPARING THEREOF - The present invention relates to chewable compositions for oral administration, said compositions comprising high(methyl)pectin, glycerol and water. Advantageously, the chewable composition can comprise a drug substance. The present invention also concerns a process for preparing the chewable composition and the use of said chewable composition as a medicament. | 2015-12-31 |
20150374623 | DEAMORPHIZATION OF SPRAY-DRIED FORMULATIONS VIA SPRAY-BLENDING - Dry powder formulations for inhalation and their use in the treatment diseases and conditions. The formulation contains a uniform blend of a first spray-dried powder and a second spray-dried powder. The first spray-dried powder contains spray-dried particles of a therapeutically active ingredient dispersed in a pharmaceutically acceptable hydrophobic excipient. The second spray-dried powder contains spray-dried particles formed from a pharmaceutically acceptable hydrophobic excipient but are substantially free of any therapeutically active ingredient. The active ingredient in the first spray-dried powder is loaded sufficiently high to compensate for the second spray-dried powder being substantially free of any active ingredient. A process for preparing such formulations is also described. | 2015-12-31 |
20150374624 | Composition For Making a Tea Beverage or Herbal and Vegetable Broths - The present invention relates to an infusion product for making a beverage, more specifically to a plant-based composition for making a beverage, and to a herbal and/or vegetable composition or bouquet garni. The plants are fruits, herbs, medicinal plants, tea, vegetables and/or spices. The invention further relates to a method for producing said compositions or infusion product, its use for making a (tea) beverage, and a (tea) beverage so obtained. Further, the present invention relates to a fiber-web, preferably a tea bag, made from said fruits, herbs, medicinal plants, tea, vegetable and/or spices. | 2015-12-31 |
20150374625 | Non Surface Active Agent Non Polymeric Agent Hydro-Alcoholic Foamable Compositions, Breakable Foams And Their Uses - A substantially surface active agent-free and substantially polymeric agent-free foamable composition which includes short-chain alcohol, water, fatty alcohol or fatty acid or a combination of fatty alcohol and fatty acid and propellant. A substantially surface active agent-free and substantially polymeric agent-free foamable composition which includes water, fatty alcohol or fatty acid and propellant. A method of treatment using a substantially surface active agent-free and substantially polymeric agent-free foamable composition. | 2015-12-31 |
20150374626 | TREATMENT OF EVOLVING BACTERIAL RESISTANCE DISEASES INCLUDING KLEBSIELLA PNEUMONIAE WITH LIPOSOMALLY FORMULATED GLUTATHIONE - The composition of the invention, liposomal glutathione, has been recently shown to have utility for having an antibiotic like effect on | 2015-12-31 |
20150374627 | NANOPARTICLES FOR DERMAL AND SYSTEMIC DELIVERY OF DRUGS - The present invention relates to a poly(lactic glycolic) acid (PLGA) nanoparticle associated with therapeutic agents for a variety of therapeutic applications. | 2015-12-31 |
20150374628 | Pharmaceutical Formulation Containing Gelling Agent - Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. | 2015-12-31 |
20150374629 | METHOD FOR FORMATION OF MICRO-PRILLED POLYMERS - A method for formation of micro-prilled poloxamer particles is disclosed. The particles find special use in pharmaceutical formulations. The process involves use of atomizing nozzles at higher than normal pressure atomizing gas, high atomizing gas temperature, use of high feed temperatures to reduce the viscosity of the poloxamer and optionally sieving after prill formation in prilling towers. The poloxamer particles are spherical and preferably have an average nominal diameter of less than or equal to 106 microns. The process is very cost effective and rapid. | 2015-12-31 |
20150374630 | Crush resistant delayed-release dosage forms - The invention relates to a dosage form comprising a physiologically effective amount of a physiologically active substance (A), a synthetic, semi-synthetic or natural polymer (C), optionally one or more physiologically acceptable auxiliary substances (B) and optionally a synthetic, semi-synthetic or natural wax (D), wherein the dosage form exhibits a resistance to crushing of at least 400 N and wherein under physiological conditions the release of the physiologically active substance (A) from the dosage form is at least partially delayed. | 2015-12-31 |
20150374631 | Pharmaceutical Formulation Containing Gelling Agent - Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. | 2015-12-31 |
20150374632 | ENTERIC COATED TABLET - To provide an enteric coated tablet containing a large amount of medicinal ingredient and having sufficient impact resistance, without forming a thick enteric coating layer. | 2015-12-31 |
20150374633 | THERMORESPONSIVE HYDROGEL CONTAINING POLYMER MICROPARTICLES FOR NONINVASIVE OCULAR DRUG DELIVERY - A method for sustained delivery of an agent to an ocular organ in a subject, comprising topically delivering to the ocular surface a liquid thermoresponsive hydrogel comprising agent-loaded polymer microparticles, wherein the agent is sustainably released for a period of at least five days. | 2015-12-31 |
20150374634 | Nanoparticles for Controlled Release of Anti-Biofilm Agents and Methods of Use - The present invention relates to compositions and methods to treat and/or prevent biofilms and biofilm related diseases. The invention comprises a nanoparticle carrier (NPC) and at least one therapeutic agent therein. The NPC binds within biofilm and to surfaces at risk for biofilm formation and accumulation while providing local, sustained, enhanced and controlled delivery of the therapeutic agent, when triggered for release. In one embodiment, the NPC comprises pH-responsive elements that allows for specific delivery of the therapeutic agent when the local environment dictates that the agent should be delivered precisely when it is most needed. | 2015-12-31 |
20150374635 | Oral pharmaceutical formulation in the form of an aqueous suspension of microcapsules for the modified release of active principle(s) - The invention relates to liquid pharmaceutical formulations for oral administration with the modified release of active principle(s), excluding amoxicillin, said formulations consisting of suspensions of coated particles of active principles (microcapsules). According to the invention, the microcapsules constituting the disperse phase of the suspension are designed to allow the modified release of the active principle(s) according to a profile that does not change during the storage of the liquid suspension. To do this the inventors propose the selection of a specific coating composition for the microcapsules which consists of at least four components that allow these microcapsules to be stored in water without modifying their properties of modified release of the active principle, this liquid phase furthermore being saturated with active principle(s). | 2015-12-31 |
20150374636 | ORAL PHARMACEUTICAL FORMULATION IN THE FORM OF AQUEOUS SUSPENSION FOR MODIFIED RELEASE OF ACTIVE PRINCIPLE(S) - The invention relates to liquid pharmaceutical formulations for oral administration with the modified release of active principle(s), excluding amoxicillin, said formulations consisting of suspensions of coated particles of active principles (microcapsules). According to the invention, the microcapsules constituting the disperse phase of the suspension are designed to allow the modified release of the active principle(s) according to a profile that does not change during the storage of the liquid suspension. To do this the inventors propose the selection of a specific coating composition for the microcapsules which consists of at least four components that allow these microcapsules to be stored in water without modifying their properties of modified release of the active principle, this liquid phase furthermore being saturated with active principle(s). | 2015-12-31 |
20150374637 | SEMI-PERMEABLE CAPSULAR MEMBRANE WITH TAPERED CONDUITS FOR DIABETES FUNCTIONAL CURE - Some embodiments of the present disclosure include an encapsulated islet for treating diabetes. The encapsulated islet may include a semi-permeable capsular membrane having a plurality of layers including an outer immunoprotection layer, a bridging layer, and an inner backbone layer, each layer having a plurality of pores, wherein the pores increase in size from the immunoprotection layer to the backbone layer, creating the tapered conduits. The semi-permeable capsular membrane may include the following layers, in order from outermost layer to innermost layer: an immunoprotection layer, a bridging layer, and a backbone layer. With proper balancing of membrane thickness and tapered pore size distribution, the encapsulated islets may offer a diabetes treatment or functional cure without immunosuppressive drugs. | 2015-12-31 |
20150374638 | ORAL PHARMACEUTICAL COMPOSITION - An oral composition comprising minicapsules wherein the minicapsules comprise one or more therapeutic or prophylactic substances in a liquid, semi-liquid, or solid core. The minicapsules have release profiles to release the substance in an active form at one or more sites along the gastro-intestinal tract to maximise absorption and/or therapeutic efficiency. | 2015-12-31 |
20150374639 | ENCAPSULATION OF HYDROPHILLIC ANTIRETROVIRAL DRUGS IN NANOCARRIERS - An encapsulated hydrophilic antiretroviral drug including a biodegradable polymeric nanoparticle and a process for fabricating biodegradable polymeric nanoparticles to encapsulate hydrophilic antiretroviral drugs are described. In an implementation, an encapsulated hydrophilic antiretroviral drug including a biodegradable polymeric nanoparticle includes a hydrophilic antiretroviral drug; and a biodegradable polymer polymeric nanoparticle that encapsulates the hydrophilic antiretroviral drug to form a nano-sized encapsulated hydrophilic antiretroviral drug. | 2015-12-31 |
20150374640 | UNIFORM FILMS FOR RAPID-DISSOLVE DOSAGE FORM INCORPORATING ANTI-TACKING COMPOSITIONS - The present invention relates to water-soluble films incorporating anti-tacking agents and methods of their preparation. Anti-tacking agents may improve the flow characteristics of the compositions and thereby reduce the problem of film adhering to a user's mouth or to other units of film. In particular, the present invention relates to edible water-soluble delivery systems in the form of a film composition including a water-soluble polymer, an active component selected from cosmetic agents, pharmaceutical agents, vitamins, bioactive agents and combinations thereof and at least one anti-tacking agent. | 2015-12-31 |
20150374641 | FILM-FORMING PHARMACEUTICAL COMPOSITION FOR WOUND HEALING AND METHOD FOR PREPARING THE SAME - The present invention relates to a pharmaceutical composition for forming a film directly on a wound to accelerate wound healing, a use for the same, a treatment method using the same, and a method for preparing the same. The film-forming composition according to the present invention forms a film directly on the wound to increase the adhesion to the wound. The formed thin hydrophilic film protects the wound surface to prevent infection of the wound surface, retains the physiologically active substance useful for wound healing on the wound surface to promote the wound healing, and allow drugs to be continuously delivered to the wound surface. Therefore, the composition according to the present invention has excellent wound healing effect and has excellent usability as it is not absorbed into clothing, bandage, etc., thus effectively replacing conventional gel or ointment formations for delivering physiologically active substances. | 2015-12-31 |
20150374642 | TRANSDERMAL PATCH - A patch containing a storage layer retaining a drug or a pharmaceutically acceptable salt thereof and an adhesive layer which are formed on a support, wherein the adhesive layer contains a thermoplastic elastomer, and a non-volatile hydrocarbon oil in more than 50 parts by weight and not more than 800 parts by weight per 100 parts by weight of the elastomer, and the adhesive layer optionally further contains a tackifier at a content of not more than 10 wt %. | 2015-12-31 |
20150374643 | COMPOSITION FOR INDUCING DIFFERENTIATION INTO BEIGE AND BROWN ADIPOCYTES AND METHOD OF INDUCING THE SAME - A composition for inducing differentiation into beige adipocytes from white adipocytes, including butein, a butein derivative, or a pharmaceutically available salt thereof as an active ingredient, and a method of inducing the differentiation are provided. Increases in expressions of UCP-1 and PRDM4 are confirmed using the active ingredient, that is, the butein or butein derivative, and therefore the composition is expected to be used in preventing or treating obesity, and more basically, for target treatment. | 2015-12-31 |
20150374644 | Therapeutic Composition for the Treatment of Perianal Disorders - A composition for the treatment of perianal disorders. In particular, the composition includes three components: a) an analgesic, b) a cryoprotective agent and c) a muscle relaxant. | 2015-12-31 |
20150374645 | DEVICES AND METHODS FOR SUSTAINED TREATMENT OF BLADDER PAIN AND IRRITATIVE VOIDING - Devices and methods are provided for treating a patient having bladder pain and/or irritative voiding symptoms. The method includes administering to the patient's bladder lidocaine or another anesthetic agent continuously over a treatment period of 24 hours or more in an amount effective to achieve a therapeutic effect which is sustained beyond the end of the treatment period. | 2015-12-31 |
20150374646 | TREATMENT OF CANCER AND OTHER CONDITIONS USING A TRANSCRIPTION FACTOR MODULATOR - The present disclosure provides novel methods for treating cancer and conditions regulatable by a transcription factor and/or cofactor using specific compounds, as well as compositions, and pharmaceutical formulations. In certain embodiments, the compounds are transcription factor modulators. | 2015-12-31 |
20150374647 | THERAPEUTIC APPROACHES FOR TREATING EPILEPSY AND RELATED DISORDERS THROUGH REDUCTION OF EPILEPTOGENESIS - The present invention relates to compositions and methods for the treatment of epilepsy and related disorders. More specifically, the present invention relates to novel combinatorial therapies of epilepsy and related disorders. | 2015-12-31 |
20150374648 | Compositions And Methods Of Use Of Phorbol Esters In The Treatment Of Neoplasms - Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of chronic and acute conditions. Such conditions may be caused by disease, be symptoms, treatments, or sequelae of disease. The phorbol esters described are particularly useful in the treatment of neoplastic diseases and/or managing the side effects of chemotherapeutic and radiotherapeutic treatments of neoplastic diseases. | 2015-12-31 |
20150374649 | Treatment of Severe Hypertriglyceridemia - Treatment of severe hypertriglyceridemia, such as Type I or Type V hyperlipoproteinemia, by therapy with MBX-8025 or an MBX-8025 salt, alone or in combination with one or more of a fibrate, niacin, and an omega-3 fatty acid, optionally accompanied by apheresis. | 2015-12-31 |
20150374650 | PHARMACEUTICAL COMPOSITIONS CONTAINING DEXKETOPROFEN AND TRAMADOL - A pharmaceutical composition as a solid oral dosage form is described, comprising:
| 2015-12-31 |
20150374651 | EXTENDED, DELAYED AND IMMEDIATE RELEASE FORMULATION METHOD OF MANUFACTURING AND USE THEREOF - Compositions for reducing the frequency of urination and methods of manufacturing the compositions are disclosed. The compositions comprises a first component having an immediate-release subcomponent and an extended-release subcomponent, wherein the first component is formulated to release the subcomponents immediately after administration; and a second component comprising an immediate-release subcomponent and an extended-release subcomponent, wherein the second component is formulated for a delayed-release of the subcomponents. | 2015-12-31 |
20150374652 | ANTIOXIDANT COMPOSITIONS FOR SOFT ORAL TISSUE AND METHODS OF FORMULATION AND USE THEREOF - One embodiment of the invention is directed to an oral antioxidant composition including between 0.0001% and 5.0% w/w antioxidant, wherein the antioxidant includes cinnamic acid derivative, tetrahydrocurcuminoids, or phloretin and an orally pharmaceutically acceptable carrier. The composition may have a pH of at least 5.0. According to still further embodiments, the composition may also include between 0.0001% and 5.0% w/w of one or two more additional antioxidants that include cinnamic acid derivative, tetrahydrcurcuminoids, phloretin, or a stilbene derivative. In more particular embodiments, the cinnamic acid derivative may include trans-ferulic acid, the tetrahydrocurcuminoids may include tetrahydrcurcuminoids CG™, or the stilbene derivative may include resveratrol. Other embodiments may relate to methods of treating or preventing an oral disease by applying topically an antioxidant composition as described above. | 2015-12-31 |
20150374653 | GASTRIC RETENTIVE PHARMACEUTICAL COMPOSITIONS FOR TREATMENT AND PREVENTION OF CNS DISORDERS - The present disclosure is directed to methods and compositions for ameliorating, preventing and treating central nervous system (CNS) disorders. The invention aims to treat subjects suffering from, susceptible to, or diagnosed with CNS disorders, and in particular, to treating patients suffering from those disorders which are associated with neurotransmitter system dysfunction. | 2015-12-31 |
20150374654 | LIPID COMPRISING DOCOSAPENTAENOIC ACID - The present invention relates to extracted plant lipid or microbial lipid comprising docosapentaenoic acid, and processes for producing the extracted lipid. | 2015-12-31 |
20150374655 | BETA-3 ADRENOCEPTOR AGONISTS FOR THE TREATMENT OF PULMONARY HYPERTENSION - The invention relates to the use of selective agonists of beta-3 adrenergic receptors for the treatment and/or prevention of pulmonary hypertension. | 2015-12-31 |
20150374656 | Compositions and methods of use of phorbol esters - Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of cytopathic diseases. Cytopathic diseases may be caused by a variety means such as viral infections like HIV and AIDS, or the development of neoplasms in a mammalian subject. The methods and compositions of the invention are effective for inhibiting de novo HIV infection, upregulating viral expression from latent provirus, inhibiting HIV-induced cytopathic effects, down regulating the HIV receptor, increasing Th1 cytokine expression, decreasing Th2 cytokine expression, increasing ERK phosphorylation, inducing apoptosis in malignant cells, inducing remission, maintaining remission, as chemotherapeutic agents, as well as for decreasing symptoms of cytopathic diseases and opportunistic infections that may accompany such diseases. Additional compositions and methods are provided which employ a phorbol ester or derivative compound in combination with at least one additional agent such as those used in HAART protocols, therapeutic agents used to treat opportunistic infections due to HIV, or chemotherapeutic agents to yield more effective treatment tools against cytopathic diseases in mammalian subjects. | 2015-12-31 |
20150374657 | METAP2 INHIBITORS AND METHODS OF TREATING OBESITY - The present invention relates to modified or polymer conjugated MetAP2 inhibitors. The present invention also relates to methods of preventing, inducing, causing or increasing weight loss, treating obesity and/or treating metabolic syndrome utilizing the modified or polymer conjugated MetAP2 inhibitors. The present invention also relates to methods of improving insulin sensitivity and glycemic control, reducing insulin levels and/or improving leptin sensitivity utilizing the modified or polymer conjugated MetAP2 inhibitors. | 2015-12-31 |
20150374658 | COMPOSITION COMPRISING LICORICIDINE - The present invention relates to a composition comprising licoricidine and at least one component selected from the group consisting of glyasperin D, glyasperin C, gancaonin I and glycyrrhisoflavone, preferably wherein said composition is a | 2015-12-31 |
20150374659 | Composition and Method for Treating Tinnitus - A method of treating tinnitus includes the step administering a composition to the mammal, wherein the composition consists essentially of a biologically effective amount of vitamin A, vitamin E, vitamin C, a vasodilator comprising magnesium, and, optionally, a withanolide, and/or resveratrol. | 2015-12-31 |
20150374660 | Ascorbate Esters of Omega-3 Fatty Acids and Their Formulations and Uses - The present invention provides ascorbate esters of omega-3 fatty acids as their pharmaceutically-acceptable salts and pharmaceutically-acceptable formulations for use as dietary supplements with enhanced antioxidant properties, in improving the effectiveness of other drugs and in treatment of hypertriglyceridemia, hypercholestolemia, diabetes, psychiatric and neurological disorders, attention deficit and hyperactivity disorder, and as cosmeceuticals. | 2015-12-31 |
20150374661 | BIOLOGICALLY ACTIVE MACROLIDES, COMPOSITIONS, AND USES THEREOF - The present invention provides a compound of the formula (I) or (II), wherein R | 2015-12-31 |
20150374662 | INHIBITORS OF BETA-CATENIN IN TREATMENT OF COLORECTAL CANCER - Compounds are disclosed which are effective for inhibiting β-catenin or disrupting a β-catenin/Tcf-4 complex, and for causing effective attenuation of colon carcinogenesis. The compounds may be effective treatment for colorectal cancer (CRC) when administered in an effective dose to a patient afflicted therewith. | 2015-12-31 |
20150374663 | Compositions and Methods for Controlled Localized Delivery of Bone Forming Therapeutic Agents - The present invention provides compositions and methods for providing controllable local delivery of a therapeutic agent to promote bone formation. In certain embodiments, the invention is used as a treatment for a subject with osteoporosis, bone cancer or bone fracture. The invention provides a therapeutic agent that is tethered to a polymer to form a therapeutic-tethered macromer, where the therapeutic agent is controllably released from the conjugate by degradation of the tether. In certain embodiments, the therapeutic agent is an inhibitor of GSK3β. In certain embodiments, the composition of the invention is specifically targeted to a site in need of bone formation. | 2015-12-31 |
20150374664 | Effective Amounts of (3aR)-1,3a,8-Trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3 b]indol-5-yl Phenylcarbamate and Methods of Treating or Preventing Neurodegeneration - The invention includes an amount of (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate for administering to a subject and also a method of preventing or treating neurotoxicity or neurodegenerative processes in a subject in need thereof using the amount thereof. | 2015-12-31 |
20150374665 | CLONIDINE FORMULATION IN A POLYORTHOESTER CARRIER - Effective treatments of acute pain for extended periods of time are provided. The treatments include the administration of one or more drug depots at or near a target site wherein the drug depots include an effective amount of clonidine formulated within a polyorthoester. By administration of one or more drug depots at or near the target site, one can relieve pain caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discongenic back pain and joint pain, as well as pain that is incidental to surgery. In some embodiments, the relief can be for at least twenty-five days, at least fifty days, at least one hundred days or at least one hundred and thirty-five days. | 2015-12-31 |
20150374666 | AQUEOUS LIQUID COMPOSITION INCLUDING HIGH CONCENTRATION OF L-HISTIDINE - Aqueous liquid compositions containing histidine at a high concentration, which is preferable for oral ingestion, are useful for the production of foods, drinks, pharmaceutical products, and the like. Particular aqueous liquid compositions contain histidine at a concentration greater than 20 wt % and may further contain a divalent or higher valent organic acid. | 2015-12-31 |
20150374667 | Compositions And Method For Treatment Of Ischemic Neuronal Reperfusion Injury - A method and composition for the treatment of ischemic neuronal reperfusion injury are provided. The composition can include a compound which is a combination of dantrolene and a residue of FMOC-valine. This composition can be used to provide a faster and higher CNS penetration than heretofore experienced with dantrolene. In another form, dantrolene may be formulated as a pro-drug, a pro-pro-drug and the like. | 2015-12-31 |
20150374668 | CHEMICAL COMPOUNDS - Disclosed are compounds of Formula III. Also disclosed are salts of the compounds, pharmaceutical composition comprising the compounds or salts, and methods for treating HCV infection by administration of the compounds or salts. | 2015-12-31 |
20150374669 | ARYL IMIDAZOLES AND THEIR USE AS ANTI-CANCER AGENTS - Therapeutically effective 2,4,5-trisubstituted imidazole compounds are provided. Also provided are methods of preparing the compounds and pharmaceutical compositions comprising the compounds alone or in combination with other agents. The present invention further provides for the use of the compounds as anti-cancer agents; wherein: R1 is aryl, substituted aryl, heterocycle, substituted heterocycle, heteroaryl, substituted heteroaryl or amino; R2 and R3 are independently aryl, substituted aryl, heterocycle, heteroaryl, substituted heterocycle, or substituted heteroaryl or R2 and R3 when taken together along with the carbon atoms they are attached to, form aryl or substituted aryl, and R4 is hydrogen, halogen, hydroxyl, thiol, lower alkyl, substituted lower alkyl, lower alkenyl, substituted lower alkenyl, lower alkynyl, substituted lower alkynyl, alkylalkenyl, alkyl alkynyl, alkoxy, alkylthio, aryl, aryloxy, amino, amido, carboxyl, aryl, substituted aryl, heterocycle, heteroaryl, substituted heterocycle, heteroalkyl, cycloalkyl, substituted cycloalkyl, alkylcycloalkyl, alkylcycloheteroalkyl, nitro, cyano or —S(O)o.2R wherein R is alkyl, substituted alkyl, aryl, substituted aryl, heterocycle, heteroaryl, substituted heterocycle, or substituted heteroaryl. | 2015-12-31 |
20150374670 | Oral Dosage Forms of Bendamustine - In the present invention there is provided a pharmaceutical composition for oral administration which comprises bendamustine or a pharmaceutically acceptable, ester, salt or solvate thereof as an active ingredient, and a pharmaceutically acceptable excipient and which shows a dissolution of the bendamustine of at least 60% in 20 minutes, 70% in 40 minutes and 80% in 60 minutes, as measured with a paddle apparatus at 50 rpm according to the European Pharmacopoeia in 500 ml of a dissolution medium at a pH of 1.5. The invention further relates to the above pharmaceutical composition for use for the oral treatment of a medical condition which is selected from chronic lymphocytic leukemia, acute lymphocytic leukaemia, chronic myelocytic leukaemia, acute myelocytic leukaemia, Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, breast cancer, ovarian cancer, small cell lung cancer and non-small cell lung cancer. | 2015-12-31 |
20150374671 | BENDAMUSTINE PHARMACEUTICAL COMPOSITIONS - The present invention provides pharmaceutical formulations of lyophilized bendamustine suitable for pharmaceutical use. The present invention further provides methods of producing lyophilized bendamustine. The pharmaceutical formulations can be used for any disease that is sensitive to treatment with bendamustine, such as neoplastic diseases. | 2015-12-31 |
20150374672 | PRE-SELECTION OF SUBJECTS FOR THERAPEUTIC TREATMENT WITH AN HSP90 INHIBITORY COMPOUND BASED ON CHEMOSENSITIVE STATUS - The present invention relates to the use of an Hsp90 inhibitor, alone or in combination with another chemotherapeutic agent, in treating cancer in subjects that are determined to be chemosensitive. In particular, the invention features a method of treating cancer in a subject, comprising administering a Hsp90 inhibitor to the subject, wherein the time since diagnosis of cancer in the subject is 6 months or greater. | 2015-12-31 |
20150374673 | Combination Therapy for the Treatment of Nosocomial Pneumonia - The present invention relates to a method of treatment of nosocomial pneumonia using a combination of ceftazidime (a third generation cephalosporin) and avibactam (a novel β-lactamase inhibitor), optionally with one or more additional therapeutic agents. | 2015-12-31 |
20150374674 | R-7-(3-AMINOMETHYL-4-METHOXYIMINO-3-METHYL-PYRROLIDIN-1-YL)-1-CYCLOPROPYL-- 6-FLUORO-4-OXO-1,4-DIHYDRO-[1,8]NAPHTHYRIDINE-3-CARBOXYLIC ACID AND L-ASPARTIC ACID SALT, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME FOR ANTIMICROBIAL - Disclosed herein are R-7-(3-aminomethyl-4-methoxyimino-3-methyl-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid and L-aspartic acid salt, process for the preparation thereof and pharmaceutical composition comprising the same for antimicrobial. Because the R-7-(3-aminomethyl-4-methoxyimino-3-methyl-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid and L-aspartic acid salt is more soluble and less toxic and has less side effects as an antimicrobial agent than hydrochloride and the other salts (D-aspartate and phosphate) conventionally used, the salt may be useful for oral and injectable administration. | 2015-12-31 |
20150374675 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF LEFT VENTRICULAR DIASTOLIC DYSFUNCTION COMPRISING AN APOLIPOPROTEIN PEPTIDE/PHOSPHOLIPID COMPLEX - The present invention features pharmaceutical compositions and methods of using pharmaceutical compositions for treating left ventricular diastolic dysfunction. In particular, the pharmaceutical compositions include an apolipoprotein complex comprising a lipid fraction and a protein fraction. | 2015-12-31 |
20150374676 | HELICASE-PRIMASE INHIBITORS FOR USE IN A METHOD OF TREATING ALZHEIMER'S DISEASE - The present invention relates to the use of helicase-primase inhibitors in a method of treating Alzheimer's Disease (AD). Particularly, the present invention relates to the use of helicase-primase inhibitors in a method of treating AD in a subject that is having HSV-1 infection and is having AD or is having HSV-1 infection and is suspected of having AD. | 2015-12-31 |
20150374677 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE - This invention provides an isolated compound having the structure: | 2015-12-31 |
20150374678 | COMPOSITIONS AND METHODS FOR INDUCING CONFORMATIONAL CHANGES IN CEREBLON AND OTHER E3 UBIQUITIN LIGASES - Provided herein are compositions, therapeutic methods, screening methods, computational methods and biomarkers based upon the elucidation of the interaction among cereblon, its substrates and certain compounds or agents, including small molecules, peptides, and proteins. | 2015-12-31 |
20150374679 | COMPOSITIONS AND METHODS FOR TREATING DISEASES OF THE NAIL - Methods and compositions for treating disorders of the nail and nail bed. Such compositions contain a vehicle in which all components of the composition are dissolved, suspended, dispersed, or emulsified, a non-volatile solvent, a wetting agent, and a pharmaceutically active ingredient that is soluble in the non-volatile solvent and/or a mixture of the vehicle and the non-volatile solvent, and which composition is effective in treating a disorder of the nail or nail bed. | 2015-12-31 |
20150374680 | POCHOXIME CONJUGATES USEFUL FOR THE TREATMENT OF HSP90 RELATED PATHOLOGIES - The present invention includes novel derivatives, analogs, and intermediates of the natural products radicicol, pochonins, pochoximes, and their syntheses. The present invention also provides a pharamceutical composition comprising the present compound and the use of the compound as inhibitors of kinases and of the enzyme family known as heat shock protein 90 (HSP90). | 2015-12-31 |
20150374681 | CONTROLLED RELEASE COMPOSITIONS FOR TREATMENT OF COGNITIVE, EMOTIONAL AND MENTAL AILMENTS AND DISORDERS - A montelukast composition having a therapeutically effective amount of montelukast in a sustained release is disclosed. A montelukast composition having a therapeutically effective amount of montelukast in an immediate release and sustained release is also disclosed. | 2015-12-31 |
20150374682 | METHODS FOR TREATING PANCREATIC CANCER USING COMBINATION THERAPIES COMPRISING LIPOSOMAL IRINOTECAN - Provided are methods for treating pancreatic cancer in a patient by administering liposomal irinotecan (MM-398) alone or in combination with additional therapeutic agents. In one embodiment, the liposomal irinotecan (MM-398) is co-administered with 5-fluorouracil and leucovorin. | 2015-12-31 |
20150374684 | COMPOSITION AND METHOD FOR TREATMENT OF DEPRESSION AND PSYCHOSIS IN HUMANS - Compositions and methods for the treatment of depression and psychoses in humans are disclosed. More particularly, the invention is directed to formulations containing antipsychotic and/or antidepressant medications and also containing an NMDAR antagonist. The present Invention Is also directed to methods tor the treatment of humans suffering from depression and other psychoses, including, schizophrenia, by administration of the inventive compositions in antidepressant and/or antipsychotic effective amounts. | 2015-12-31 |
20150374685 | PULMONARY DELIVERY OF A FLUOROQUINOLONE - A composition for pulmonary administration comprises a fluoroquinolone betaine, such as ciprofloxacin betaine, and an excipient. In one version, the particles have a mass median aerodynamic diameter from about 1 μm to about 5 μm, and the fluoroquinolone has a half life in the lungs of at least 1.5 hours. The composition is useful in treating an endobronchial infection, such as | 2015-12-31 |
20150374686 | Methods of Treating Flushing Associated with Carcinoid Tumors and Carcinoid Syndrome - A method of treating flushing associated with carcinoid tumors and carcinoid syndrome in a patient in need thereof comprising topically applying a pharmaceutical composition comprising an effective amount of an alpha adrenergic receptor agonist, pharmaceutically acceptable salt thereof, or combinations thereof; and a pharmaceutically acceptable carrier to the site of the flushing is claimed. | 2015-12-31 |
20150374687 | SUBSTITUTED QUINOXALINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR4 - The present invention relates to novel quinoxaline derivatives as positive allosteric modulators for modulating metabotropic glutamate receptor subtype 4 (mGluR4) and/or altering glutamate level or glutamatergic signalling. | 2015-12-31 |
20150374688 | Solid oral pharmaceutical compositions comprising fixed dose combination of metformin and sitagliptin or salts thereof. - The present invention provides solid oral pharmaceutical compositions comprising combination of metformin and sitagliptin or salts thereof. In particular, the present invention relates to a multilayered coated pharmaceutical composition comprising at least two compartments of metformin or salts thereof exhibiting immediate and extended release and at least one compartment of sitagliptin and metformin or salts thereof exhibiting immediate release. The invention also includes process of preparing such compositions and method of use of such compositions for treating type II diabetes. | 2015-12-31 |
20150374689 | Use of Levosimendan to Treat Left Ventricular Systolic Dysfunction in Patients Undergoing Cardiac Surgery Requiring Cardiopulmonary Bypass - Methods of (i) reducing morbidity and/or mortality in a human patient undergoing cardiac surgery; (ii) preventing, or reducing the risk of development of, LCOS in a human patient undergoing cardiac surgery; or (iii) reducing the risk of, intensity of, or occurrence of, one or more postoperative adverse events in a human patient undergoing cardiac surgery. The methods can involve (a) a first period of administering to the patient levosimendan for about 1 hour, in which the administration of levosimendan during the first period is initiated: (i) before skin incision for the cardiac surgery, and (ii) at an infusion dose of about 0.2 μg/kg/min; and (b) a second period of administering to the patient levosimendan for about 23 hours, in which the administration of levosimendan during the second period is initiated at an infusion dose of about 0.1 μg/kg/min. | 2015-12-31 |
20150374690 | HETEROARYL COMPOUNDS AND USES THEREOF - The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same. | 2015-12-31 |
20150374691 | METHODS AND MATERIALS FOR TREATING ORTHOSTATIC HYPOTENSION OR POSTURAL TACHYCARDIA SYNDROME - This document provides methods and materials related to treating orthostatic hypotension and/or postural tachycardia syndrome. For example, methods and materials for using a composition containing 3,4-diaminopyridine, 4-aminopyridine, or both to treat patients with orthostatic hypotension, postural tachycardia syndrome, or both orthostatic hypotension and postural tachycardia syndrome are provided. | 2015-12-31 |
20150374692 | METHODS AND COMPOSITIONS RELATING TO THE TREATMENT OF CANCER - The compositions and methods described herein relate to the treatment of cancer, e.g. by reducing the regression of cancer cells from regressing into cancer stem cell-like phenotypes and/or reducing the development of drug-resistant cancer cells. In some embodiments, the compositions and methods relate to inhibitors of PI3K pathway kinases and Src family kinases. | 2015-12-31 |
20150374693 | Fused Bicyclic 2,4-diaminopyrimidine Derivative as a Dual ALK and FAK Inhibitor - The present invention provides a compound of formula (I) | 2015-12-31 |
20150374694 | TGF-BETA ENHANCING COMPOSITIONS FOR CARTILAGE REPAIR AND METHODS RELATED THERETO - This disclosure relates to compounds and compositions for cartilage repair and methods related thereto. In certain embodiments, the disclosure relates to methods of inducing cartilage growth and regeneration comprising administering an effective amount of a composition comprising a compound disclosed herein to the subject or implanting a cartilage matrix comprising a compound disclosed herein in the subject. In certain embodiments, the compound is used locally such as injection at any desired site of cartilage formation. | 2015-12-31 |
20150374695 | 6-PIPERAZINYL-3,4-DIHYDROQUINAZOLIN-2(1H)-ONES - A series of new 6-piperazinyl-3,4-dihydroquinazolin-2(1H)-ones have been synthesized. The compounds are structurally related to adoprazine, a potential atypical antipsychotics bearing potent D | 2015-12-31 |
20150374696 | WNT PROTEIN SIGNALLING INHIBITORS - The present invention generally relates to protein signalling. In particular, compounds that inhibit the Wnt protein signalling pathway are disclosed. Such compounds may be used in the treatment of Wnt protein signalling-related diseases and conditions such as cancer, degenerative diseases, type II diabetes and osteopetrosis. | 2015-12-31 |
20150374697 | ORGANIC COMPOUNDS - The present invention relates to compounds and compositions useful for inhibiting and/or reducing platelet deposition, adhesion and/or aggregation. The present invention further relates to methods for the treatment or prophylaxis of thrombotic disorders, including stroke, myocardial infarction, unstable angina, peripheral vascular disease, abrupt closure following angioplasty or stent placement and thrombosis as a result of vascular surgery. | 2015-12-31 |
20150374698 | THERAPEUTIC STRATEGIES FOR THE TREATMENT OF PREECLAMPSIA - Compositions and methods for treating preeclampsia in a subject in need thereof are disclosed. | 2015-12-31 |
20150374699 | NOVEL USES - The invention relates to the administration of inhibitors of phosphodiesterase 1 (PDE1) for the treatment of diseases or disorders characterized by disruption of or damage to various cGMP/PKG mediated pathways. In one embodiment the invention relates to inhibitors of phosphodiesterase 1 (PDE1) for treatment of cardiovascular disease and related disorders, e.g., congestive heart disease, atherosclerosis, myocardial infarction, and stroke. | 2015-12-31 |